AN AUDIT OF TREATMENT OF GENITAL WARTS - OPENING THE FEEDBACK LOOP

被引：8

作者：

REYNOLDS, M ^{[1
]}

MURPHY, M ^{[1
]}

WAUGH, MA ^{[1
]}

LACEY, CJN ^{[1
]}

机构：

[1] GEN INFIRM,DEPT GENITOURINARY MED,GREAT GEORGE ST,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 1993年 / 4卷 / 04期

关键词：

AUDIT; GENITAL WARTS; TREATMENT PROTOCOL;

D O I：

10.1177/095646249300400410

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An audit of the treatment of patients (100 men and 90 women) presenting with a first episode of anogenital warts to the Genitourinary Medicine Department at Leeds General Infirmary was performed. Treatment of patients was monitored for a period of 6 months from the time of presentation. The management of patients with genital warts lacked a clearly defined strategy and treatment was unselective and poorly monitored. Excluding patients who defaulted, at follow-up 44 (44%) men and 36 (38%) women still had genital warts at 3 months. Of those patients clear of warts at 3 months, the mean time to remission for men and women was 7.1 and 8.3 weeks respectively. Podophylin 25% in tincture of benzoin was by far the predominant therapeutic modality used. A total of 96 (96%) men and 76 (84%) women received treatment with podophyllin. Both male and female patients had a mean of 5 treatments with podophyllin 25% (range 1-19 and 1-12 respectively). Physical methods of treatment i.e. cryotherapy and electrocautery, were underutilized, both as primary therapies and when topical agents had failed. Patients saw an average of 3 (range 1-7) doctors over the course of their treatment. Patients with warts affecting 2 or more sites, male patients with anal/perianal warts, and female patients with cervical and vaginal warts had higher failure rates from treatment at 3 months. On the basis of these findings, specific treatment protocols for the management of anogenital warts have been devised.

引用

页码：226 / 231

页数：6

共 23 条

[1]

New cases seen at NHS genitourinary medicine clinics in England’Summary information from form KC60—1990/91, (1992)

[2]

Krogh V., Rylander E., Therapeutic possibilities, GPVI-genitoanal papilloma virus infection, pp. 127-177, (1989)

[3]

Margolis S., Therapy for Condyloma acuminatum: A review, Rev Infect Dis, 4, pp. 829-836, (1982)

[4]

Kraus S.J., Stone K.M., Management of genital infection caused by human papillomavirus, Rev Infect Dis, 12, pp. 620-632, (1990)

[5]

Kinghorn G.R., Genital papillomavirus infections: Treatment, Recent Advances in Sexually Transmitted Diseases., 3, pp. 147-155, (1986)

[6]

Handley J.M., Horner T., Maw R.D., Lawther H., Dinsmore W.W., Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: A randomised observer blind placebo controlled study, Genitourin Med, 67, pp. 297-302, (1991)

[7]

Krebs H.B., Management of human papillomavirus associated lesions in men, Obstet Gynecol, 73, pp. 312-316, (1989)

[8]

von Krogh G., Topical treatment of penile condylomata acuminata with podophyllin, podophyilotoxin and colchicine, Acta Derm Venerol, 58, pp. 163-168, (1978)

[9]

Persistent anogenital warts, Lancet, 338, pp. 1114-1116, (1991)

[10]

von Krogh G., Podophyilotoxin for condylomata acuminata eradication. Clinical and experimental comparative studies on podophyllum lignans, colchicine and 5-flurouracil, Acta Derm Venerol, 98, pp. 1-48, (1981)

← 1 2 3 →